Company Overview

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery, and proprietary software to locate, target, and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian’s targeting accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who may not previously have been considered radiation therapy candidates. ViewRay believes MRIdian may improve the safety and efficacy of radiation therapy, potentially leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Financial News

Date Title and Summary Additional Formats
Toggle Summary World's First MRIdian Center Treats 1,000th Patient with MRI-Guided Radiation Therapy
Extensive Clinical Experience at Siteman Cancer Center Helps Further Adoption and Clinical Practice of MR-guided and On-Table Adaptive Radiation Therapy CLEVELAND , May 22, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the clinical team at Siteman Cancer Center at
Toggle Summary ViewRay® to Present at the Jefferies 2019 Global Healthcare Conference
CLEVELAND , May 16, 2019 /PRNewswire/ --  ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will participate in the Jefferies 2019 Global Healthcare Conference in New York, New York . Scott Drake , President and CEO, will participate in a fireside chat at 8:30 a.m.
Toggle Summary ViewRay Reports First Quarter 2019 Results
CLEVELAND , May 2, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the first quarter ended March 31, 2019 . First Quarter 2019 Highlights: Received 7 new orders for MRIdian systems totaling $42.8 million , compared to 3 orders totaling $21.2 million in the
Toggle Summary ViewRay's MRIdian to be Featured at Leading European Radiation Oncology Meeting
26 Clinical Presentations and Posters Highlight Benefits of MRI-Guided Radiation Therapy Across Applications and Growing Use of Adaptive Therapy CLEVELAND , April 23, 2019 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Financial Events
More events are coming soon.

E-mail Alerts

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!
Click here for E-mail Alerts

Transfer Agent
American Stock Transfer & Trust Company, LLC
6201 15th Avenue
Brooklyn, NY 11219
(800) 937-5449

In Need of Customer Support? Contact

  Language Select